Disease severity and costs among patients starting a treatment with COX-2 specific inhibitors versus NSAIDs patients in Italy: Quantitative assessment in 442 patients with arthritis

被引：0

作者：

Lucioni, C

Chinellato, A

Mazzi, S

Roggeri, D

Chiroli, S

机构：

[1] Adis Int Ltd, Milan, Italy

[2] Serv Farmaceut Terr, Treviso, Italy

[3] Pharmacia Italia SpA, Milan, Italy

来源：

VALUE IN HEALTH | 2002年 / 5卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)61270-3

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：476 / 477

页数：2

共 50 条

[41] The comparative healing of gastric ulcers with esomeprazole versus ranitidine in patients taking either continuous COX-2 selective NSAIDs or nonselective NSAIDs
Goldstein, JL
Johanson, J
Hawkey, CJ
Suchower, L
Levine, D
GASTROENTEROLOGY, 2004, 126 (04) : A610 - A610
[42] The comparative healing of gastric ulcers with esomephazole versus ranitidine in patients taking either continuous COX-2 selective NSAIDs or nonselective NSAIDs
Goldstein, JL
Johanson, JF
Hawkey, CJ
Suchower, LJ
Levine, D
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 519 - 519
[43] Increase in lifetime adverse drug reactions and increased disease severity among patients who will start COX-2 agents: Quantitative assessment of confounding by indication in 6,689 RA and OA patients.
Wolfe, F
Flowers, N
Burke, T
Arguelles, L
Pettitt, D
ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S225 - S225
[44] Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study
Bakhriansyah, Mohammad
Souverein, Patrick C.
de Boer, Anthonius
Klungel, Olaf H.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (10) : 1141 - 1148
[45] Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors
Zhao, SZ
Burke, TA
Whelton, A
von Allmen, H
Henderson, SC
AMERICAN JOURNAL OF MANAGED CARE, 2002, 8 (15): : S401 - S413
[46] Blood pressure control and edema rates in older patients with hypertension and osteoarthritis following treatment with COX-2 specific inhibitors
Whelton, A
White, WB
Fort, JG
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 244A - 244A
[47] Blood pressure control and edema rates in older patients with hypertension and osteoarthritis following treatment with COX-2 specific inhibitors
Whelton, A
White, WB
Fort, JG
JOURNAL OF HYPERTENSION, 2002, 20 : S82 - S82
[48] Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports
Sanchez-Matienzo, David
Arana, Alejandro
Castellsague, Jordi
Perez-Gutthann, Susana
CLINICAL THERAPEUTICS, 2006, 28 (08) : 1123 - 1132
[49] Celecoxib, a COX-2 specific inhibitor, is associated with a lower incidence of serious upper gastrointestinal (UGI) events in arthritis patients than comparator NSAIDs.
Goldstein, JL
Agrawal, NM
Silverstein, F
Hubbard, RC
Zhao, W
Geis, GS
ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S280 - S280
[50] Serum COX-2 and FOXO3a in patients with rheumatoid arthritis and correlation with disease activity
Wang, Bangqin
Huang, Xinxiang
Lin, Jinying
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (02) : 910 - 916

← 1 2 3 4 5 →